|
1
|
Brooks SE, Zhan M, Cote T and Baquet CR:
Surveillance, epidemiology, and end results analysis of 2677 cases
of uterine sarcoma 1989–1999. Gynecol Oncol. 93:204–208.
2004.PubMed/NCBI
|
|
2
|
D’Angelo E and Prat J: Uterine sarcomas: a
review. Gynecol Oncol. 116:131–139. 2010.
|
|
3
|
Major FJ, Blessing JA, Silverberg SG, et
al: Prognostic factors in early-stage uterine sarcoma. A
Gynecologic Oncology Group study. Cancer. 71(Suppl 4): 1702–1709.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zagouri F, Dimopoulos AM, Fotiou S,
Kouloulias V and Papadimitriou CA: Treatment of early uterine
sarcomas: disentangling adjuvant modalities. World J Surg Oncol.
7:382009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ryan CW, Dolan ME, Brockstein BB, et al: A
phase II trial of O6-benzylguanine and carmustine in patients with
advanced soft tissue sarcoma. Cancer Chemother Pharmacol.
58:634–639. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Woll PJ, Judson I, Lee SM, et al:
Temozolomide in adult patients with advanced soft tissue sarcoma: a
phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur
J Cancer. 35:410–412. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trent JC, Beach J, Burgess MA, et al: A
two-arm phase II study of temozolomide in patients with advanced
gastrointestinal stromal tumors and other soft tissue sarcomas.
Cancer. 98:2693–2699. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Talbot SM, Keohan ML, Hesdorffer M, et al:
A phase II trial of temozolomide in patients with unresectable or
metastatic soft tissue sarcoma. Cancer. 98:1942–1946. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garcia del Muro X, Lopez-Pousa A, Martin
J, et al; Spanish Group for Research on Sarcomas. A phase II trial
of temozolomide as a 6-week, continuous, oral schedule in patients
with advanced soft tissue sarcoma: a study by the Spanish Group for
Research on Sarcomas. Cancer. 104:1706–1712. 2005.
|
|
10
|
Anderson S and Aghajanian C: Temozolomide
in uterine leiomyosarcomas. Gynecol Oncol. 98:99–103. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferriss JS, Atkins KA, Lachance JA,
Modesitt SC and Jazaeri AA: Temozolomide in advanced and recurrent
uterine leiomyosarcoma and correlation with o6-methylguanine DNA
methyltransferase expression: a case series. Int J Gynecol Cancer.
20:120–125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esteller M, Hamilton SR, Burger PC, Baylin
SB and Herman JG: Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter hypermethylation
is a common event in primary human neoplasia. Cancer Res.
59:793–797. 1999.PubMed/NCBI
|
|
13
|
Herfarth KK, Brent TP, Danam RP, et al: A
specific CpG methylation pattern of the MGMT promoter region
associated with reduced MGMT expression in primary colorectal
cancers. Mol Carcinog. 24:90–98. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaina B, Fritz G, Mitra S and Coquerelle
T: Transfection and expression of human O6-methylguanine-DNA
methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of
MGMT in protection against the genotoxic effects of alkylating
agents. Carcinogenesis. 12:1857–1867. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Franceschi E, Tosoni A, Pozzati E and
Brandes AA: Association between response to primary treatments and
MGMT status in glioblastoma. Expert Rev Anticancer Ther.
8:1781–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hassel JC, Sucker A, Edler L, et al: MGMT
gene promoter methylation correlates with tolerance of temozolomide
treatment in melanoma but not with clinical outcome. Br J Cancer.
103:820–826. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smith E, Jones ME and Drew PA:
Quantitation of DNA methylation by melt curve analysis. BMC Cancer.
9:1232009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kowalewska M, Danska-Bidzinska A,
Bakula-Zalewska E and Bidzinski M: Identification of suitable
reference genes for gene expression measurement in uterine sarcoma
and carcinosarcoma tumors. Clin Biochem. 45:368–371. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cui W, Taub DD and Gardner K:
qPrimerDepot: a primer database for quantitative real time PCR.
Nucleic Acids Res. 35:D805–809. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jacinto FV and Esteller M: MGMT
hypermethylation: a prognostic foe, a predictive friend. DNA Repair
(Amst). 6:1155–1160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Preusser M, Charles Janzer R, Felsberg J,
et al: Anti-O6-methylguanine-methyltransferase (MGMT)
immunohistochemistry in glioblastoma multiforme: observer
variability and lack of association with patient survival impede
its use as clinical biomarker. Brain Pathol. 18:520–532. 2008.
|
